- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07857070
Newborn Brain Assessment - CergenX Wave (NBT)
Determining Grade of Neonatal Encephalopathy - Agreement Between the Modified Sarnat Examination and Automated AI Assessment of Newborn Brain Function Using Wave Software
In this study we want to assess how a newly developed software device called CergenX Wave compares to the modified Sarnat examination, performed by the neonatology team . The Wave software algorithm (which is a set of rules used by the computer) analyses EEG activity, using four electrodes placed on the neonate's scalp.
A portable EEG machine records the EEG activity and a tablet will send this information to the cloud where the device analyses the data, as shown in the figure below. The EEG activity the Wave device evaluates will not be available to either the research or clinical team during the investigation but once the recording is completed the device will display a code on screen for the research team to confirm completion.
The results will not be visible to either the researchers or the clinical team therefore will not in any way influence the care of the neonate. This is a regulated observational investigation to compare how the software performs against the current standard of care, a standardised neurological examination.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Brian Walsh, Neonatologist
- Numero di telefono: +353214920525
- Email: brianhenry.walsh@ucc.ie
Luoghi di studio
-
-
Cork
-
Cork, Cork, Irlanda
- Cork University Maternity Hospital
-
Contatto:
- Aisling Fanning
- Numero di telefono: +353214920525
- Email: aisling.fanning1@hse.ie
-
-
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75235
- University of Texas Southwestern Medical Center
-
Contatto:
- Lina Chalak
- Numero di telefono: 214-648-3060
- Email: Lina.Chalak@UTSouthwestern.edu
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Infants at high-risk of Neonatal Encephalopathy
Descrizione
Inclusion Criteria:
-
Infants born at ≥36+0 weeks gestational age
-
Informed consent obtained AND
-
A pH of ≤7.0 or base deficit ≥16 (on cord or 1st infant blood gas at < 1 hour of life) OR
-
a) A pH of 7.01-7.15 or base deficit ≥ 16 (on cord or 1st infant blood gas at < 1 hour of life) WITH b) at least one of the following:
-
An APGAR score ≤5 at 10 minutes OR
-
Prolonged resuscitation (infant receiving IPPV at ≥10 minutes of life) OR
-
An acute perinatal event:
- Abnormal CTG (variable/late foetal HR decelerations)
- Foetal bradycardia
- Prolapsed/ruptured/tight nuchal cord
- Shoulder dystocia
- Uterine rupture
- Maternal haemorrhage/placental abruption
- Maternal trauma (e.g. vehicle accident)
- Mother received CPR
-
Exclusion Criteria:
- Infants < 36 weeks gestation
- No parental/guardian consent
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: CASE_ONLY
- Prospettive temporali: PROSPECTIVE
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Neonates
Neonates at risk of Neonatal Encephalopathy |
The amplifier is used to acquire and transmit the EEG to the CergenX Wave software that is installed in a COTS computer.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Percentage agreement between the CergenX Wave result and stage of NE assigned by modified Sarnat examination (i.e. normal/mild abnormality versus moderate/severe abnormality) between 1-6 hours of life
Lasso di tempo: From the enrolment and up to 6 hours after birth
|
From the enrolment and up to 6 hours after birth
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in agreement between the modified Sarnat examination and the software-based assessment from the initial assessment (1-6 hours of life) to 24 hours of life (± 6 hours) among infants with initial disagreement.
Lasso di tempo: From enrolment of the participant and up to 30 hours after birth
|
From enrolment of the participant and up to 30 hours after birth
|
|
|
Level of agreement between modified Sarnat examination, Wave software, and aEEG/cEEG classification at the same time point in infants with available neurophysiologic monitoring.
Lasso di tempo: From enrolment of the participant and up to 30 hours after birth
|
From enrolment of the participant and up to 30 hours after birth
|
|
|
Association between CergenX Wave software and clinical variables including discharge diagnosis
Lasso di tempo: From enrolment of the participant and up to 30 hours after birth
|
Discharge diagnoses will be based on the clinical teams ultimate determination, and for analysis will be stratified as perinatal asphyxia without encephalopathy, mild neonatal encephalopathy, moderate encephalopathy, severe encephalopathy or alternate diagnosis. Descriptive statistics will be used to explore the frequency of the output of the Wave device with these diagnoses |
From enrolment of the participant and up to 30 hours after birth
|
|
Assessment of healthcare professional (device users) satisfaction with usability of the device.
Lasso di tempo: From enrolment of the participant and up to 30 hours after birth
|
An adapted System Usability Scale (SUS) will be used, referred to as a User Experience Questionnaire that utilises a Likert scale. |
From enrolment of the participant and up to 30 hours after birth
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- 25116
- DT 2023 0435 (Altro numero di sovvenzione/finanziamento: Department of Enterprise, Tourism and Employment. Enterprise Ireland)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .